ライフサイエンスコーパス: monocyte chemoattractant protein-1

1 iated inflammatory mediators (in particular, monocyte chemoattractant protein-1).

2 eta), tumor necrosis factor (TNF), IL-6, and monocyte chemoattractant protein 1.

3 ression of proinflammatory interleukin 6 and monocyte chemoattractant protein 1.

4 ut increased amounts of gamma interferon and monocyte chemoattractant protein 1.

5 necrosis factor-beta, interferon-gamma, and monocyte chemoattractant protein-1.

6 ming systemic inflammation was the chemokine monocyte chemoattractant protein-1.

7 their migration in response to the chemokine monocyte chemoattractant protein-1.

8 nd secretion of the proinflammatory cytokine monocyte chemoattractant protein-1.

9 th-regulated oncogene-alpha (GRO-alpha), and monocyte chemoattractant protein-1.

10 splanted visceral fat pad and reduced plasma monocyte chemoattractant protein-1.

11 cated in endogenous fat inflammation such as monocyte chemoattractant protein-1.

12 f intercellular cell adhesion molecule-1 and monocyte chemoattractant protein-1.

13 a-like ligand 4, apelin, angiopoietin-2, and monocyte chemoattractant protein-1.

14 nitric oxide synthase 3, thrombomodulin, and monocyte chemoattractant protein-1.

15 5%, P < 0.002; interleukin-6, 13%, P < 0.01; monocyte chemoattractant protein-1, 10%, P < 0.0006) and

16 or necrosis factor-alpha (-16% versus +12%), monocyte chemoattractant protein-1 (-13% versus +0.2%),

17 creases in interleukin-6 (21%; P < 0.02) and monocyte chemoattractant protein 1 (14% decrease at 4 wk

18 ange messenger RNA: interleukin-1beta = 7.6, monocyte chemoattractant protein-1 = 15.3, and tumor nec

19 ations of inflammatory biomarkers, including monocyte chemoattractant protein-1 (adjusted OR 9.0 [95%

20 ls of IL-6, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 after stimulation wit

21 increased CD68, tumor necrosis factor alpha, monocyte chemoattractant protein-1, alpha-smooth muscle

22 remote myocardium (e.g., 12-fold increase of monocyte chemoattractant protein-1), although levels wer

23 increases in CC chemokine ligand 2 (CCL2, or monocyte chemoattractant protein-1), an important macrop

24 adhesion molecule 1, soluble E-selectin, and monocyte chemoattractant protein 1 and cancer risk.

25 diponectin and leptin while reducing that of monocyte chemoattractant protein 1 and interleukin-8 by

26 eotaxin, IL-2, and IL-12 and the chemokines monocyte chemoattractant protein 1 and keratinocyte-deri

27 alveolar epithelial cells produced excessive monocyte chemoattractant protein 1 and reactive oxygen s

28 Systemic LDL oxidation and monocyte chemoattractant protein 1 and the expression of

29 In RAW264.7 cells, allosamidin elevated monocyte chemoattractant protein 1 and tumor necrosis fa

30 flammatory factors (interleukin-6 and -8 and monocyte chemoattractant protein-1 and -2), and mobiliza

31 n the vascular wall (decreased production of monocyte chemoattractant protein-1 and activation of p38

32 ukin-6, tumor necrosis factor) and adaptive (monocyte chemoattractant protein-1 and CXCL10 chemokines

33 plasia and pro-inflammatory gene expression (monocyte chemoattractant protein-1 and cytokine-induced

34 or necrosis factor-alpha, interleukin-6, and monocyte chemoattractant protein-1 and decreased M2 mark

35 ry and proproliferative mediators, including monocyte chemoattractant protein-1 and hypoxia-inducible

36 Seeded BMCs secreted significant amounts of monocyte chemoattractant protein-1 and increased early m

37 d at the promoters of the inflammatory genes monocyte chemoattractant protein-1 and interleukin-6 in

38 in significantly reduced production of serum monocyte chemoattractant protein-1 and interleukin-6 lev

39 lial selectin surface expression and reduced monocyte chemoattractant protein-1 and interleukin-6 pro

40 -infected MSKO mouse livers had: (1) greater monocyte chemoattractant protein-1 and macrophage inflam

41 Unlike WT mice, induction of monocyte chemoattractant protein-1 and macrophage migrat

42 ased expression of the proinflammatory gene, monocyte chemoattractant protein-1 and matrix metallopro

43 NA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein-1 and reduced mRNA and

44 25(OH)(2)D(3) supplementation also inhibited monocyte chemoattractant protein-1 and stimulated adipon

45 macrophages showed reduced migration toward monocyte chemoattractant protein-1 and transmigration th

46 uction of key proatherogenic factors such as monocyte chemoattractant protein-1 and tumor necrosis fa

47 h plaque stabilization and downregulation of monocyte chemoattractant protein-1 and ubiquitin.

48 okine (C-C motif) ligand 5 and expression of monocyte chemoattractant protein-1 and vascular cell adh

49 oliferating cell nuclear antigen+ cells, and monocyte chemoattractant protein-1 and vascular cell adh

50 sAPPbeta) and two neuroinflammatory markers (monocyte chemoattractant protein-1 and YKL-40) were meas

51 he TLR9 (toll-like receptor 9), IFNG, MCP-1 (monocyte chemoattractant protein-1) and GM-CSF genes, an

52 ed with increased renal expression of MCP-1 (monocyte chemoattractant protein-1) and VLA-4 (very-late

53 necrosis factor alpha, interleukin-6, CCL2 (monocyte chemoattractant protein 1), and CCL5 (RANTES).

54 F-beta, connective tissue growth factor, and monocyte chemoattractant protein 1), and epithelial-to-m

55 induced inflammation (tumor necrosis factor, monocyte chemoattractant protein 1, and chemokine [C-X-C

56 s of myeloperoxidase, tumor necrosis factor, monocyte chemoattractant protein 1, and gamma interferon

57 eukin 1beta (IL-1beta), IL-6, CXCL1/KC, CCL2/monocyte chemoattractant protein 1, and granulocyte colo

58 terleukin-6, keratinocyte-derived chemokine, monocyte chemoattractant protein 1, and interleukin-10),

59 e, with extremely high mRNA levels for IL-8, monocyte chemoattractant protein 1, and macrophage infla

60 asminogen activator receptor, interleukin-6, monocyte chemoattractant protein 1, and matrix metallopr

61 ene and protein expression of tissue factor, monocyte chemoattractant protein-1, and cyclooxygenase-2

62 ated lipocalin, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and fractional hypox

63 on- gamma , interleukin [IL]-4, IL-10, IL-6, monocyte chemoattractant protein-1, and growth-regulated

64 dependent increase in release of IL-6, IL-8, monocyte chemoattractant protein-1, and growth-regulated

65 with statistically different levels of IL-6, monocyte chemoattractant protein-1, and heat-shock prote

66 ed secretion of tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and interleukin-12.

67 lecule-1, intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and interleukin-17A;

68 increased expression of inflammatory genes, monocyte chemoattractant protein-1, and interleukin-6, a

69 pha, macrophage inflammatory protein-1alpha, monocyte chemoattractant protein-1, and keratinocyte-der

70 irculating levels of P-selectin, E-selectin, monocyte chemoattractant protein-1, and macrophage conte

71 atory cytokines tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and macrophage infla

72 lating factor, keratinocyte chemoattractant, monocyte chemoattractant protein-1, and macrophage infla

73 , soluble intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and P-selectin.

74 Suppression of ED-1, monocyte chemoattractant protein-1, and RANTES expressio

75 L-8, IL-10, interferon-inducible protein-10, monocyte chemoattractant protein-1, and tumor necrosis f

76 roinflammatory cytokines (interleukin-1beta, monocyte chemoattractant protein-1, and tumor necrosis f

77 neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and tumor necrosis f

78 neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and tumor necrosis f

79 ession of intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and vascular endothe

80 NA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein-1 as 129/B6-ApoE(-/-) c

81 r alpha and interleukin-6) and the chemokine monocyte chemoattractant protein 1 at levels indistingui

82 ficantly with matrix metalloproteinase-3 and monocyte chemoattractant protein-1 at baseline, biomarke

83 iR-132 and demonstrated that miR-132 induces monocyte chemoattractant protein-1 at least in part via

84 ellular protease plasmin cleaves mouse MCP1 (monocyte chemoattractant protein 1) at lysine 104, relea

85 m levels of CD40 ligand, serum amyloid A and monocyte chemoattractant protein-1, (b) limited evidence

86 from WKY rats synthesized significantly more monocyte chemoattractant protein-1 basally and after sti

87 7/BL6 mice, markedly augmented the levels of monocyte chemoattractant protein-1 bound to RBCs, which

88 macrophage inflammatory protein-1alpha, and monocyte chemoattractant protein-1, but it did not exert

89 of tumor necrosis factor, interleukin-6, and monocyte chemoattractant protein 1 by spleen cells was a

90 osis factor-alpha, IL-1beta, IL-6, IL-8, and monocyte chemoattractant protein-1 by co-cultured dendri

91 IL-8, granulocyte colony-stimulating factor, monocyte chemoattractant protein-1, C-reactive protein,

92 ssive neuroblastoma, repressed expression of monocyte chemoattractant protein-1/CC chemokine ligand 2

93 terferon [IFN-gamma], and IL-6), chemokines (monocyte chemoattractant protein 1/CCL-2, macrophage inf

94 Monocyte chemoattractant protein 1 (CCL2) is a recently

95 ll alpha chemoattractant (I-TAC/CXCL11), and monocyte chemoattractant protein 1 (CCL2) were measured

96 CD163 (sCD163) and soluble CD14 (sCD14), and monocyte chemoattractant protein 1 (CCL2) with subclinic

97 d PGE(2)-induced production of the chemokine monocyte chemoattractant protein-1 (CCL2), which was lin

98 an IC50 of 22.8 nM but was inactive against monocyte chemoattractant protein-1 (CCL2)-mediated calci

99 d-brain barrier leakage, induction of MCP-1 (monocyte chemoattractant protein 1) (CCL2), ICAM-1 (inte

100 of histamine, cytokines, and the chemokines monocyte chemoattractant protein 1/CCL2, macrophage infl

101 n stimulation with CXCL16 astrocytes release monocyte chemoattractant protein-1/CCL2 and (2) the neur

102 crosis factor-alpha) and chemokines (such as monocyte chemoattractant protein-1/ chemokine (C-C motif

103 biomarkers (glial fibrillary acidic protein, monocyte chemoattractant protein 1/chemokine (C-C motif)

104 glial fibrillary acidic protein (p = 0.002), monocyte chemoattractant protein 1/chemokine (C-C motif)

105 leukin-8/C-X-C motif chemokine ligand 8, and monocyte chemoattractant protein-1/chemokine ligand 2 in

106 8/C-X-C motif chemokine ligand 8 P=0.04, and monocyte chemoattractant protein-1/chemokine ligand 2 P=

107 ts contained increased leptin, resistin, and monocyte chemoattractant protein-1 compared with plasma

108 12p40, interferon-inducible protein 10, and monocyte chemoattractant protein 1 concentrations, where

109 Monocyte chemoattractant protein-1 concentrations in nas

110 growth factor, hepatocyte growth factor and monocyte chemoattractant protein-1, contributing to deve

111 enes such as tumor necrosis factor-alpha and monocyte chemoattractant protein-1, decreased AT inflamm

112 of THP-1 monocytes to migrate toward MCP-1 (monocyte chemoattractant protein 1) depended upon Par3 a

113 nside-out activation of beta(2) integrins by monocyte chemoattractant protein-1 did not change IL-13-

114 In vitro, IL-6 markedly increased monocyte chemoattractant protein-1-driven monocyte-to-my

115 in 6, macrophage inflammatory protein 2, and monocyte chemoattractant protein 1 expression as determi

116 y reduced hepatic inflammation, particularly monocyte chemoattractant protein-1 expression and macrop

117 ell as vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 expression in endothe

118 n, normal T cell expressed and secreted) and monocyte chemoattractant protein-1 expression induced by

119 tin on vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 expression.

120 ating vascular cell adhesion molecule -1 and monocyte chemoattractant protein-1 expressions.

121 proinflammatory mediators interleukin-6 and monocyte chemoattractant protein-1, fibroblast growth fa

122 The monocyte chemoattractant protein 1 gene (MCP-1) is regul

123 nterferon gamma-inducible protein of 10 kDa, monocyte chemoattractant protein 1, growth-related oncog

124 binding oligomerization domain containing-2, monocyte chemoattractant protein-1, IL-2, and IL-12p40 i

125 micked by stimulation of Hmox1(+/+) SCs with monocyte chemoattractant protein-1, IL-6, IL-1beta, and

126 tate dehydrogenase, as well as expression of monocyte chemoattractant protein-1, IL-6, IL-1beta, and

127 NA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein 1 in lumbar spinal cord

128 hyper-IgE syndrome generated lower levels of monocyte chemoattractant protein 1 in response to the pr

129 okines, including keratinocyte chemokine and monocyte chemoattractant protein 1 in toxin A-exposed mi

130 n, normal T cell expressed and secreted) and monocyte chemoattractant protein-1 in a mouse model of o

131 tic lesion areas and decreased expression of monocyte chemoattractant protein-1 in the aorta as compa

132 amma, tumor necrosis factor-alpha, IL-8, and monocyte chemoattractant protein-1 in the spleen.

133 Five inflammatory markers (IL-6, IL-8, monocyte chemoattractant protein-1, interferon-gamma-ind

134 GE and other proinflammatory genes including monocyte chemoattractant protein-1, interferon-gamma-ind

135 accumulation, apoptosis, necrotic cores, and monocyte chemoattractant protein 1, interleukin 1beta, i

136 inflammatory response through alteration of monocyte chemoattractant protein-1, interleukin-1beta, a

137 of cytokines keratinocyte-derived chemokine, monocyte chemoattractant protein-1, interleukin-6 (IL-6)

138 lasminogen activator inhibitor-1, TNF-alpha, monocyte chemoattractant protein-1, interleukin-6, and k

139 m TK-/- mice exhibited blunted production of monocyte chemoattractant protein-1, interleukin-6, and m

140 oduction of cytokines and chemokines, namely monocyte chemoattractant protein-1, interleukin-6, and m

141 icantly higher levels of expression of cKIT, monocyte chemoattractant protein-1, interleukin-6, strom

142 ion, as denoted by the reduced expression of monocyte chemoattractant protein-1, intracellular adhesi

143 Monocyte chemoattractant protein-1 is a chemokine recrui

144 cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1, is markedly increase

145 ial protein expression of interleukin-18 and monocyte chemoattractant protein-1, key mediators of car

146 ction was strongly correlated with increased monocyte chemoattractant protein 1 levels (r = 0.396, P

147 eased plasma tumor necrosis factor-alpha and monocyte chemoattractant protein-1 levels in Tg-hCBS apo

148 igation and puncture, and interleukin 10 and monocyte chemoattractant protein-1 levels were higher in

149 indicated Cr elevations correlated with CSF monocyte chemoattractant protein-1 levels.

150 ed plasma interleukin-6, interleukin-10, and monocyte chemoattractant protein-1 levels.

151 ing factor were significantly reduced, while monocyte chemoattractant protein 1, macrophage inflammat

152 es were induced to produce chemokines (e.g., monocyte chemoattractant protein 1, macrophage inflammat

153 protein-1alpha, and C-reactive protein, and monocyte chemoattractant protein-1, macrophage inflammat

154 Upregulation of monocyte chemoattractant protein-1, macrophage inflammat

155 terferon-gamma inducible protein-10 [IP-10], monocyte chemoattractant protein-1, macrophage inflammat

156 ngII-induced expression of cyclooxygenase-2, monocyte chemoattractant protein-1, macrophage inflammat

157 ing tumor necrosis factor alpha (TNF-alpha); monocyte chemoattractant protein 1; macrophage inflammat

158 heal had higher tumor necrosis factor-alpha, monocyte chemoattractant protein-1, matrix metallopeptid

159 ssion of the fibrocyte recruiting chemokines monocyte chemoattractant protein 1 (MCP-1) and CXCL12, a

160 ed, there was a significant decrease in CCL2/monocyte chemoattractant protein 1 (MCP-1) and inflammat

161 stability of tumor necrosis factor alpha and monocyte chemoattractant protein 1 (MCP-1) but strongly

162 low-density lipoprotein (ox-LDL)-stimulated monocyte chemoattractant protein 1 (MCP-1) from macropha

163 d various levels of interleukin-8 (IL-8) and monocyte chemoattractant protein 1 (MCP-1) in response t

164 lammatory cytokines interleukin-8 (IL-8) and monocyte chemoattractant protein 1 (MCP-1) in response t

165 ssion of the inflammatory mediators CD36 and monocyte chemoattractant protein 1 (MCP-1) in the brain

166 While monocyte chemoattractant protein 1 (MCP-1) is known to b

167 Monocyte chemoattractant protein 1 (MCP-1) mediates acut

168 Although the M-CSF and monocyte chemoattractant protein 1 (MCP-1) mRNA levels w

169 Monocyte chemoattractant protein 1 (MCP-1) peaked postdi

170 Monocyte chemoattractant protein 1 (MCP-1) plays a pivot

171 We showed previously that monocyte chemoattractant protein 1 (MCP-1) was a critica

172 Recently, increased expression of monocyte chemoattractant protein 1 (MCP-1) was reported

173 ar adhesion molecule 1 (ICAM-1), E-selectin, monocyte chemoattractant protein 1 (MCP-1), and interleu

174 Of the 21 cytokines tested, monocyte chemoattractant protein 1 (MCP-1), keratinocyte

175 ter infection (day 2), interleukin 6 (IL-6), monocyte chemoattractant protein 1 (MCP-1), macrophage i

176 anulocyte colony-stimulating factor (G-CSF), monocyte chemoattractant protein 1 (MCP-1), macrophage i

177 s of IFN-gamma-inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage i

178 IL-12, and IL-18; chemokines, such as IL-8, monocyte chemoattractant protein 1 (MCP-1), RANTES, and

179 rogenase, and inflammatory mediators such as monocyte chemoattractant protein 1 (MCP-1), TNF-alpha, a

180 lammatory mediators, including TNF-alpha and monocyte chemoattractant protein 1 (MCP-1).

181 gration via increased expression of IL-6 and monocyte chemoattractant protein 1 (MCP-1).

182 , we show that T. cruzi strongly upregulates monocyte chemoattractant protein 1 (MCP-1)/CCL2 and frac

183 l-derived factor 1alpha (SDF-1alpha)/CXCL12, monocyte chemoattractant protein 1 (MCP-1)/CCL2, and vas

184 Monocyte chemoattractant protein 1 (MCP-1/CCL2) is a pro

185 , S1P stimulated secretion of the chemokine, monocyte chemoattractant protein 1 (MCP-1/CCL2), from th

186 ctants were induced in the kidney, including monocyte chemoattractant protein 1 (MCP-1/CCL2), macroph

187 Recently, we have identified monocyte chemoattractant protein 1 (MCP-1; CCL2) as a pr

188 Monocyte chemoattractant protein-1 (MCP-1 or CCL2) regul

189 ion, associated with 38% reduced circulating monocyte chemoattractant protein-1 (MCP-1) and 36% lower

190 6), tumor necrosis factor-alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1) and C-reactiv

191 Very high plasma levels of monocyte chemoattractant protein-1 (MCP-1) and interleuk

192 ited TNF-alpha-induced inflammatory factors, monocyte chemoattractant protein-1 (MCP-1) and interleuk

193 so increased levels of inflammatory cytokine monocyte chemoattractant protein-1 (MCP-1) and MCP-1 ind

194 trong association between the stimulation of monocyte chemoattractant protein-1 (MCP-1) and the anabo

195 h as interleukin (IL)-6, IL-1beta, IL-8, and monocyte chemoattractant protein-1 (MCP-1) and the secre

196 d and is accompanied by increases in mRNA of monocyte chemoattractant protein-1 (MCP-1) and tumor nec

197 VSMC stimulated by TGF-beta/AdSmad3 revealed monocyte chemoattractant protein-1 (MCP-1) as a likely f

198 pirfenidone impaired macrophage migration to monocyte chemoattractant protein-1 (MCP-1) as well as IL

199 an obligate dimeric mutant of the chemokine monocyte chemoattractant protein-1 (MCP-1) by substituti

200 Monocyte chemoattractant protein-1 (MCP-1) directs migra

201 uced Src and STAT3 tyrosine phosphorylation, monocyte chemoattractant protein-1 (MCP-1) expression an

202 JNK as the exclusive mediator of FFA-induced monocyte chemoattractant protein-1 (MCP-1) expression in

203 15(S)-HETE also induced monocyte chemoattractant protein-1 (MCP-1) expression vi

204 mation, in association with higher levels of monocyte chemoattractant protein-1 (MCP-1) expression.

205 Monocyte chemoattractant protein-1 (MCP-1) is involved i

206 atment with p38 MAPK inhibitor reduced renal monocyte chemoattractant protein-1 (MCP-1) levels, the n

207 a murine model of an arteriovenous fistula, monocyte chemoattractant protein-1 (MCP-1) mRNA and prot

208 Monocyte chemoattractant protein-1 (MCP-1) plays a role

209 Monocyte chemoattractant protein-1 (MCP-1) plays an impo

210 These cells produced monocyte chemoattractant protein-1 (MCP-1) upon PIM trea

211 The chemokine monocyte chemoattractant protein-1 (MCP-1) was cooperati

212 Previously, monocyte chemoattractant protein-1 (MCP-1) was demonstra

213 ile inducing inflammatory cytokine (IL-6 and monocyte chemoattractant protein-1 (MCP-1)) expression.

214 mobility mass spectrometry (IMMS) to analyze monocyte chemoattractant protein-1 (MCP-1), a CC chemoki

215 Monocyte chemoattractant protein-1 (MCP-1), a CC-motif c

216 in HK-2 cells to stimulate the production of monocyte chemoattractant protein-1 (MCP-1), a key chemok

217 -1beta (IL-1beta), the cytokines IL-8, IL-6, monocyte chemoattractant protein-1 (MCP-1), and growth-r

218 yperactivation of ERK and p38 in response to monocyte chemoattractant protein-1 (MCP-1), and increase

219 phage accumulation, diminished expression of monocyte chemoattractant protein-1 (MCP-1), and lower le

220 activation-regulated chemokine (TARC), IL-8, monocyte chemoattractant protein-1 (MCP-1), and murine b

221 Stroke outcome, expression of brain CD36, monocyte chemoattractant protein-1 (MCP-1), CCR2, and pl

222 The role of the chemokine, monocyte chemoattractant protein-1 (MCP-1), elevated in

223 The expression of monocyte chemoattractant protein-1 (MCP-1), intercellula

224 d beta2-integrins, cyclooxygenase-2 (COX-2), monocyte chemoattractant protein-1 (MCP-1), interleukin-

225 We have previously shown that the chemokine, monocyte chemoattractant protein-1 (MCP-1), is a mediato

226 Analysis of mice lacking monocyte chemoattractant protein-1 (MCP-1), MCP-3, MCP-5

227 ge inflammatory protein-1alpha (MIP-1alpha), monocyte chemoattractant protein-1 (MCP-1), regulated on

228 n-gamma-inducible protein of 10 kDa (IP-10), monocyte chemoattractant protein-1 (MCP-1), tumor necros

229 netic basis of circulating concentrations of monocyte chemoattractant protein-1 (MCP-1), we conducted

230 n WAT and an increase of the proinflammatory monocyte chemoattractant protein-1 (MCP-1).

231 appaB pathway, which increased production of monocyte chemoattractant protein-1 (MCP-1).

232 expression of the proinflammatory cytokine, monocyte chemoattractant protein-1 (MCP-1).

233 high levels of interleukin (IL)-6, IL-8, and monocyte chemoattractant protein-1 (MCP-1).

234 and selective induction of the CC chemokine monocyte chemoattractant protein-1 (MCP-1).

235 tion, as measured by decreased expression of monocyte chemoattractant protein-1 (MCP-1).

236 chemotaxis can be signaled by the chemokine monocyte chemoattractant protein-1 (MCP-1)/CCL2 (CC chem

237 that interact with the oligomeric chemokine Monocyte Chemoattractant Protein-1 (MCP-1)/CCL2 with dif

238 rated increased expression of iNOS, C1r, and monocyte chemoattractant protein-1 (MCP-1); MCP-1 expres

239 RK) to mechanically trigger the secretion of monocyte chemoattractant protein-1 (MCP-1, also known as

240 ort the expression profile of the chemokine, monocyte chemoattractant protein-1 (MCP-1, CCL2), during

241 Genetic deletions of monocyte chemoattractant protein-1 (MCP-1, CCL2), fracta

242 to chronic pain includes the upregulation of monocyte chemoattractant protein-1 (MCP-1/CCL2) and its

243 proinflammatory cytokine IL-6 and chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2) in respo

244 keratinocytes up-regulated the expression of monocyte chemoattractant protein-1 (MCP-1/CCL2), TNFalph

245 CCR2 on its interactions with the chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2).

246 Monocyte chemoattractant protein-1 (MCP-1; CCL2)-mediate

247 mor necrosis factor alpha (TNF-alpha), CCL2 (monocyte chemoattractant protein 1 [MCP-1]), and CCL5 (R

248 6), and chemokine (C-C motif) ligand (CCL2) (monocyte chemoattractant protein 1 [MCP-1]).

249 ines (interleukin 6 [IL-6], IL-8, IL-1alpha, monocyte chemoattractant protein 1 [MCP-1], and colony-s

250 atory cytokines (interleukin-6 [IL-6], IL-8, monocyte chemoattractant protein 1 [MCP-1], and IL-1beta

251 we show that TXA(2) mimetic, I-BOP, induced monocyte chemoattractant protein -1(MCP-1)/chemokine (C-

252 ce was observed, certain chemokines (RANTES, monocyte chemoattractant protein 1[MCP-1], and IP-10) we

253 eoprotegerin (OPG) expression and increasing monocyte chemoattractant protein 1 (MCP1) expression in

254 rleukin-6 (Il-6), interleukin-1beta (Il-1b), monocyte chemoattractant protein 1 (Mcp1), and fibrosis-

255 ic pain, and mice overexpressing its ligand, monocyte chemoattractant protein-1 (MCP1; also known as

256 ential of mouse melanoma cells in HDAC3- and monocyte chemoattractant protein 1-(MCP1)-dependent mann

257 CI and other wild type CC chemokines, MCP-1 (monocyte chemoattractant protein-1), MIP-1beta, and RANT

258 10]), and proinflammatory cytokines (MCP-1 [monocyte chemoattractant protein 1], MIP-1alpha/beta [ma

259 essed and secreted, T-cell activation-3, and monocyte chemoattractant protein-1 mRNAs were lower comp

260 SkMCs released IL-6, IL-8, and monocyte chemoattractant protein-1 on Hsp60 stimulation.

261 llular adhesion molecule-1 (p < 0.0001), and monocyte chemoattractant protein-1 (p = 0.0004).

262 cellular adhesion molecule-1 (p = 0.01), and monocyte chemoattractant protein-1 (p = 0.01).

263 kin-6 (P=0.01), isoprostanes (P=0.0002), and monocyte chemoattractant protein-1 (P=0.008); SAT only r

264 proteinase 9, metalloproteinase inhibitor 1, monocyte chemoattractant protein-1, P-selectin, fibrinog

265 Expression of tumor necrosis factor-alpha, monocyte chemoattractant protein-1, plasminogen activato

266 e (C-C motif) ligand 2 (CCL2), also known as monocyte chemoattractant protein-1, plays a critical rol

267 with increased lipopolysaccharide-stimulated monocyte chemoattractant protein 1 production by JR-CSF

268 educed IL-4, IL-5, IL-13, eotaxin, IL-8, and monocyte chemoattractant protein 1 production without af

269 found a 3-fold increase in interleukin-6 and monocyte chemoattractant protein-1 production by G2A(-/-

270 Pio also did not attenuate Ang II-induced monocyte chemoattractant protein-1 production in PPARgam

271 responses to TLR2 and TLR4 ligands, reduced monocyte chemoattractant protein-1 production, and preve

272 ammation, limits neutrophils recruitment and monocyte chemoattractant protein-1 production, thus redu

273 yte/macrophage migration rather than reduced monocyte chemoattractant protein-1 production.

274 cts of Klotho signaling on interleukin-8 and monocyte chemoattractant protein-1 promoter recruitment

275 Monocyte chemoattractant protein-1 provides independent

276 isoprostanes, R2 0.07 versus 0.10, P=0.002; monocyte chemoattractant protein-1, R2 0.07 versus 0.08,

277 ed with the changes of tubular expression of monocyte chemoattractant protein-1, RANTES (regulated up

278 sis included higher levels of interleukin-8, monocyte chemoattractant protein-1, resistin, soluble in

279 ophage inflammatory protein 1alpha/beta, and monocyte chemoattractant protein 1, respectively, as det

280 and 1/lymphotactin and CC chemokine ligand 2/monocyte chemoattractant protein 1 reveal that invariant

281 Given its unique role, future studies into monocyte chemoattractant protein-1's exact role during s

282 hly associated with urinary isoprostanes and monocyte chemoattractant protein-1 (SAT versus VAT compa

283 sociated phospholipase A2 mass and activity, monocyte chemoattractant protein-1, soluble endothelial

284 methylarginine, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, soluble vascular cel

285 toreceptor cultures exposed to starvation or monocyte chemoattractant protein-1-stimulated (MCP-1-sti

286 yed similar up-regulation of miR-132/212 and monocyte chemoattractant protein-1, supporting in vivo r

287 This was associated with marked increase in monocyte chemoattractant protein-1 synthesis in WKY glom

288 emokine, C-C motif chemokine ligand 2 (CCL2; monocyte chemoattractant protein 1), termed mNOX-E36, in

289 erestingly, higher levels of interleukin 22, monocyte chemoattractant protein 1, TNF-alpha, and IP-10

290 in systolic BP, heart rate variability, and monocyte chemoattractant protein-1, together with reduce

291 nes for interleukin (IL)-1beta, IL-6, IL-10, monocyte chemoattractant protein-1, tumor necrosis facto

292 Monocyte chemoattractant protein-1 was measured at basel

293 ray indicated that the chemokine CCL2/MCP-1 (monocyte chemoattractant protein-1) was strongly induced

294 vels of IFN-gamma, interleukin-6 (IL-6), and monocyte chemoattractant protein 1 were detected in the

295 ), monokine induced by interferon-gamma, and monocyte chemoattractant protein 1 were quantified as me

296 itive cells) and production of the chemokine monocyte chemoattractant protein-1 were significantly bl

297 , intercellular cell adhesion molecule-1 and monocyte chemoattractant protein-1, were also determined

298 idenced by the upregulation of ephrin B2 and monocyte chemoattractant protein-1, which are 2 stretch-

299 oprotein 1 stimulates macrophages to secrete monocyte chemoattractant protein-1, which then activates

300 nd decreased production of oxidant-inducible monocyte chemoattractant protein-1, which we have previo